Myosteatosis, low BMI and low alanine aminotransferase levels correlate with skeletal volume loss in patients with chronic liver disease, especially among women, according to recently published data.
“Severe skeletal muscle volume loss has more recently been recognized as an indicator of cachexia and appears to be a strong negative prognostic factor in cirrhosis and several chronic diseases, as well as in malignancies, irrespective of cancer diagnosis, stage, and treatment,” Yoshihiko Tachi, MD, from the Komaki City Hospital, Japan, and colleagues wrote. “The results of the present study demonstrate that myosteatosis may serve as a novel biomarker for prognosis in patients with chronic liver disease who frequently undergo [computed tomography (CT)] as part of surveillance programs.”
To read the full story, visit: Healio
High consumption of red and processed meat linked to non-alcoholic fatty liver disease and insulin resistance
Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease
Raising awareness about alcohol-related liver disease in women
Subscribe to the EASL newsletter